The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies

Table 1 Patients’ Characteristics

Characteristics	Number	%
Age (years)
Median (IQR)	61 (18)
≦60	24	49.0
> 60	25	51.0
Gender
Male	22	44.9
Female	27	55.1
Performance status
0	29	59.2
1	13	26.5
2	6	12.2
3	1	2.0
Location of primary site
Extremities	18	36.7
Head and neck	9	18.4
Trunk	16	32.7
Unknown	6	12.2
Type
Acral melanoma	15	30.6
Non-acral cutaneous melanoma	5	10.2
Mucosal melanoma	16	32.7
Others	7	14.3
Unknown	6	12.2
Stage
3	6	12.2
4, M1a	5	10.2
4, M1b	8	16.3
4, M1c	30	61.2
BRAF gene mutation
No	34	69.4
Yes	9	18.4
Unknown	6	12.2
Treatment regimen
Nivolumab	33	67.3
Pembrolizumab	16	32.7
Immunotherapy therapy
First-line	31	63.3
Second-or later-line	18	36.7
Response
CR	2	4.1
PR	3	6.1
SD	9	18.4
PD	29	59.2
N/A	6	12.2

IQR interquartile range, CR complete response, PR partial response, SD stable disease, PD progressive disease, N/A not assessed

ISSN: 1471-2407